Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
L Gandhi, D Rodríguez-Abreu, S Gadgeel… - NEW ENGLAND …, 2018 - iris.unito.it
Background First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
[PDF][PDF] Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel… - N Engl J …, 2018 - thesilverfridge.com
BACKGROUND First-line therapy for advanced non–small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
[PDF][PDF] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L Gandhi, D Rodriguez-Abreu, S Gadgeel, E Esteban… - 2018 - repository.ubn.ru.nl
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L Gandhi, D Rodríguez Abreu… - … England Journal of …, 2018 - accedacris.ulpgc.es
Background. First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L Gandhi, D Rodríguez-Abreu… - The New England …, 2018 - pubmed.ncbi.nlm.nih.gov
Background First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L Gandhi, D Rodríguez-Abreu… - NEW ENGLAND …, 2018 - irinsubria.uninsubria.it
BACKGROUND First-line therapy for advanced non-small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
[PDF][PDF] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
F De Angelis, M Domine, P Clingan… - N Engl J …, 2018 - pure.manchester.ac.uk
BACKGROUND First-line therapy for advanced non–small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
[引用][C] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L Gandhi, M Myllärniemi… - … England Journal of …, 2018 - researchportal.helsinki.fi
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer — University of
Helsinki Skip to main navigation Skip to search Skip to main content University of Helsinki …
Helsinki Skip to main navigation Skip to search Skip to main content University of Helsinki …
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban… - ikm.ku.dk
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …